Dear Editor: Antipsychotics, both typical and atypical, have been known to lower seizure threshold. Aripiprazole is a novel atypical antipsychotic that is a partial agonist at dopamine D 2 and serotonin 1A (5-HT 1A ) receptors and has antagonist activity at the 5-HT 2 receptor. The risk of seizures with aripirazole is reported to be 0.1% (1) , the lowest among atypical agents. Our literature search revealed no report of seizure induction with aripiprazole.
Case Report
Mr A, aged 31 years, was brought to the emergency department after a motor vehicle accident. He had lost control of his vehicle, which landed in a ditch. He carried a diagnosis of delusional disorder and major depression; aripiprazole 15 mg daily had recently been added to sertraline 150 mg daily that he had been taking for the past 2 years. Both the patient and his family suspected that a seizure had caused the accident, since they were perplexed by the circumstances of the crash. The patient denied that he had attempted suicide. Mr A was restarted on aripiprazole while he was in the intensive care unit. About 3 weeks later, he had a witnessed partial complex seizure on the ward. There was no evidence of any medical cause for the seizure. His laboratory tests were within normal limits, except for a serum magnesium level of 1.7 mg/dL (the lower normal being 1.8 mg/dL). He was started on levetiracetam, and his aripiprazole was later discontinued, because it was considered to be the offending agent. The patient was subsequently transferred to the rehabilitation unit, where he stayed seizure-free. He was discharged home after an adequate recovery.
Discussion
Seizure induction from antipsychotic drugs is not a new phenomenon. Several risk factors are known, including a personal or family history of epilepsy, head trauma, and concomitant use of another drug known to lower seizure threshold (2) . Since experience with aripiprazole is limited at this time, the risk of lowering of seizure threshold with this drug may actually be higher than reported in the premarketing studies. Our patient possibly had 2 separate seizures, one of which was the witnessed event that occured when the medication was reinitiated, making the likelihood high that aripiprazole was the offender.
Medical causes were ruled out, and there were no other implicated medications.
For optimum outcomes, high vigilence is needed to promptly identify the cause of seizures in patients taking psychotropic medications. The relevence of seizure secondary to aripiprazole needs further elucidation.
Prevalence of Bipolar Disorder and Major Depression Among Patients Seen in Primary and Secondary Care in Finland
Dear Editor: The underdiagnosis of bipolar disorder (BD) and its frequent misdiagnosis as major depressive disorder (MDD) appear to be major problems in patients with BD. Few studies focus on the prevalence of BD and MDD among primary care and psychiatric service patients. In Finland, more than 66% of the population visit a community health care centre during a year; 5% of the population are treated in primary care for a mental disorder, and 3% receive psychiatric treatment (1).
The Finnish Tampere Depression Project (TADEP) was a study that used the Present State Examination (9th version) to assess the prevalence of BD and MDD in primary and secondary care. The Index of Definition cutoff point of > 4 was used to identify cases of BD (ICD-8 diagnosis 296.1). A DSM-III-R assessment was also carried out. The study setting, patients, and data collection methods are reported in detail elsewhere (2, 3) .
Results
A total of 437 patients in primary care and 435 patients in secondary care were interviewed. In community health centres, the 1-month and 12-month prevalences of BD were 0.9% and 2.1%, respectively. In community mental health centres, the corresponding figures were 4.4% and 7.6%. In comparison, the 1-month and 12-month prevalence rates of depression were 10.7% and 20.0%, respectively, in primary care, and 49.3% and 56.5%, respectively, in secondary care (3).
Thus, the 1-month and 12-month prevalence rates for depression were 4.8-fold and 3.6-fold, respectively, in primary care and 11.2-fold and 7.4-fold, respectively, in secondary care, compared with the prevalence rates for BD.
Discussion
These results may help in detecting and estimating the proportions of patients with BD in actual clinical practice. However, the possibilities of generalizing from the results are limited, owing to the country-specific health care system. The prevalence and enrichment of BD and unipolar MDD accords with other studies in the sense that BDs represent 10% to 20% of all mood disorders.
The Need for More Community Nursing for Adults With Intellectual Disabilities and Mental Health Problems
Dear Editor: We are concerned about the lack of community nursing in our geographical area for adults with intellectual disabilities and mental health problems (that is, a dual diagnosis) and the significant impact this has on our patients and their caregivers. To put this issue into context, individuals with intellectual disabilities are at greater risk than the general population for mental health problems and undiagnosed medical problems.
Psychotropic medications can be highly effective when used to treat specific psychiatric disorders in this population, but they are frequently overused and undermonitored (1) . Many individuals are unable to report unpleasant or potentially dangerous medication side effects and depend on caregivers to recognize problems. Caregivers in turn may lack training and skills in the area of medication administration and monitoring for side effects. Community nursing support has been identified as an appropriate and cost effective way to follow these individuals in the community and work with their caregivers, families, and family physicians (2).
Our specialized, interdisciplinary mental health team serves a region with a population of approximately 900 000 adults (3) of whom an estimated 7500 have a dual diagnosis (assuming a 2.25% prevalence rate of intellectual disabilities in the general population and a 38% prevalence rate of psychiatric problems in individuals with intellectual disabilities, 4). We know of 4 full-time nurses who work with this patient population. By comparison, a study in the UK reported a mean of 2.4 community nurses per 100 000 population who were specifically trained to work with adults with intellectual disabilities (5) . If we use data from the UK as a reference point, an area our size would support 21.6 such nurses, rather than the present 4.
We contend that enhanced community nursing would ensure better continuity of care for our dual-diagnosis patients and allow increased on-site monitoring and opportunities to educate caregivers about psychiatric disorders and medication effects and side effects. Moreover, it would enable psychiatrists who specialize in dual diagnosis to consult more efficiently with family physicians.
We provide actual case examples to illustrate some of our points.
Case 1
After a patient with challenging behaviour was again referred, the team discovered that the consulting psychiatrist's recommendation to decrease the patient's neuroleptic medication, made 2 years earlier to the family physician and shared with the group home staff, had not been carried out. This medication's side effects contributed to the behaviour that precipitated the second referral. Moreover, the patient's current staff did not seem to be aware that these recommendations had ever been made.
Case 2
Over a period of several weeks, caregivers had been giving a patient twice the prescribed dosage of neuroleptic medication. The patient experienced severe facial tics and contortions that developed into a serious dystonic reaction. The team was called in because the patient's behaviour was deemed to be out of control. The facial tics and contortions were not mentioned at the time of the call.
Case 3
Staff called the team because a patient was confused and drowsy, had slurred speech, and was unsteady on his feet. Upon visiting the group home, the team nurse learned that the patient, who was taking lithium, was recovering from a flu-like illness but that his vomiting continued. The nurse found him to be severely dehydrated; she advised staff to discontinue the lithium until the patient's blood level had been checked and to take him to emergency immediately. Blood work revealed that the patient had lithium toxicity.
We would be interested to hear of the experience of others in regard to these issues.
